The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

Wed, 24th Oct 2018 10:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Barclays, up 0.9%. The bank reported a rise in third quarter profit but year-to-date profit remained lower, dragged by litigation costs and conducts charges experienced earlier in the year.For the three months ended September, Barclays pretax profit increased sharply to GBP1.46 billion from GBP1.11 billion in the third quarter of 2017. The improvement was led by Barclays investment bank, which helped the Barclays International division to a 30% rise in profit. The group raised its third quarter dividend to 2.5 pence from 1.0p paid a year before. Barclays reiterated its intention to pay a total dividend of 6.5p for 2018.----------International Consolidated Airlines Group up 1.5%. Deutsche Bank raised is rating on European Airlines sector to Overweight from Underweight. easyJet was up 0.5%.----------FTSE 100 - LOSERS----------Fresnillo, down 2.7%. The gold miner revised its annual production guidance after having mixed results in the third quarter. The company said gold production in the three months to the end of September 30 declined by 3.5% to 225,000 ounces, while silver production increased by 6.3% year-on-year to 15.5 million ounces. However, Fresnillo said third-quarter silver production was not as high as anticipated and reduced its annual guidance for silver output to between 62.0 million and 64.5 million ounces from 64.5 million to 67.5 million ounces estimated earlier. Fresnillo now expects to produce between 920,000 and 940,000 ounces of gold in the full year, up from 900,000 to 930,000 ounces guided previously. Fellow gold miner Randgold Resources was down 1.7%.----------FTSE 250 - WINNERS----------Equiniti, up 0.6%. The payments services provider won two pension administration contracts in the UK nuclear sector. Under the terms of the contracts, Equiniti's pension division, EQPaymaster, will support virtually all employees and former employees engaged in the UK nuclear industry. The contracts are for the UK Atomic Energy Authority and for the Combined Nuclear Pension Plan, covering 60,000 members in total.----------FTSE 250 - LOSERS----------Metro Bank, down 7.9%. The challenger bank said it is experiencing continued competition in residential mortgages resulting in "slowed margin progress". Net interest margin fell by 15 basis points to 1.82%. More positively, Metro Bank reported lending growth of 52% in the first nine months to GBP13.12 billion from GBP8.61 billion, with commercial loans up 43% to GBP4.17 billion and residential mortgages up 59% to GBP8.72 billion. Underlying pretax profit multiplied to GBP39.2 million from GBP13.2 million, while statutory pretax profit jumped to GBP25.1 million from GBP7.8 million. At the end of the period, the bank's assets stood at GBP20.57 billion, up 41% year-on-year, while its loan to deposit ratio grew to 89% from 80%. Its Common Equity Tier 1 Capital ratio remained robust at 15.7% as at September-end. ----------Stobart Group, down 5.4%. The infrastructure & support services company swung to a loss in the first half of its financial year, despite a 21% increase in revenue. For the six months to August 31, Stobart reported a pretax loss of GBP18.8 million compared with a GBP111.6 million profit in the same period a year ago. Interim revenue increased to GBP151.3 million from GBP124.6 million year-on-year. The company's profit was hurt by the lack of income generated by the sale of its 49% interest in the parent of Eddie Stobart, Greenwhitestar Holding Co 1, which resulted in a GBP123.8 million profit figuring in its interim balance sheet a year ago. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Photo-Me International, up 10%. The photo-booth operator maintained its annual guidance following the completion of restructuring of its Japanese unit. Photo-Me said it removed unprofitable machines and installed new ones with a "significantly" lower production cost. As a result, the company expects to have a 35% faster return on its Japanese investment. Photo-Me said its deployment of encrypted photo ID upload technology has "continued to progress well", with 2,700 photo booths in the UK now enabled for UK passport renewals. The company is now targeting the deployment of 4,000 enabled photo booths by the end of December.----------OTHER MAIN MARKET AND AIM - LOSERS----------Yu Group, down 83%. The gas & electricity supplier said it expects a GBP10 million reduction in profit, which will send it to a loss, after discovering areas of concern in a performance review. One of the areas of concern for the group was the recognition of historic accrued income, which totalled GBP4.2 million for 2017 and GBP4.3 million for the six months to June. The level of trade debtors held also caused concern to the group, as if found that the level of non-payment being experienced is "significantly above that which has been previously provided for". Looking ahead, despite being "extremely disappointed" to reveal the profitability drop, Yu said it expects to achieve a profit in 2019. ----------Scancell Holdings, down 15%. The biopharmaceutical company said the US Food & Drug Administration has asked for further information on its SCIB1 product's proposed trial. Scancell applied for an investigational new drug application to the FDA for SCIB1, which will be trialled in combination with pembrolizumab in patients with advanced melanoma. The trial is being carried out alongside Ichor Medical Systems Inc's TriGrid electroporation delivery system, and it is further information on this that the US regulator has asked for. The system, Scancell said, has been used on the previous SCIB1 phase 1/2 stud, which had favourable results.----------
More News
25 Apr 2019 11:19

Scancell gets go-ahead for UK second phase trials of 'SCIB1'

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.

Read more
8 Apr 2019 11:34

Scancell Holdings expands IP protection with Japanese patent

(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.

Read more
8 Apr 2019 11:27

Scancell Gets Japan Patent Protecting Moditope Immunotherapy Platform

LONDON (Alliance News) - Scancell Holdings PLC on Monday said the Japanese Patent Office has granted a patent providing protection for its Moditope immunotherapy platform.The cancer said T

Read more
20 Mar 2019 13:38

Scancell Holdings Gets Further Patent Protection In US And Europe

LONDON (Alliance News) - Immunotherapy firm Scancell Holdings PLC has received a new patent for its Modi-1 drug candidate in the US, it said on Wednesday.The patent, granted by the US in in

Read more
31 Jan 2019 13:59

Loss Widens As Scancell Continues Moditope Cancer Vaccine Development

LONDON (Alliance News) - Scancell Holdings PLC on Thursday said its loss widened in the first half of its year on mounting administrative expenses as its development of Moditope in Scancell were a

Read more
31 Jan 2019 09:48

Scancell shares slip as losses widen in first half

(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.

Read more
23 Jan 2019 11:20

Scancell loses out on Cancer Research UK grant

(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.

Read more
23 Jan 2019 10:41

WINNERS & LOSERS SUMMARY: Metro Bank Slumps 29% On Annual Profit Miss

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 1.9%. The airline was extending gains a

Read more
23 Jan 2019 10:18

Scancell Cancer Vaccine Project Misses Out On Cancer Research UK Grant

LONDON (Alliance News) - Scancell Holdings PLC said Wednesday its Project Blueprint proposal was not selected for the Cancer Research UK Grand Challenge grant.Shares in Scancell were down -

Read more
21 Jan 2019 12:58

Scancell Appoints New Head Of Research And Manufacturing Divisions

LONDON (Alliance News) - Scancell Holdings PLC on Monday said it appointed two new executives as head of research and head of manufacturing.Samantha Paston joined Scancell as head of in She

Read more
21 Jan 2019 12:30

Scancell appoints new heads of research and manufacturing

(Sharecast News) - Immunotherapy developer Scancell Holdings announced the appointment of Dr Samantha Paston as its head of research, and Dr Adrian Parry as its head of manufacturing, on Monday.

Read more
30 Oct 2018 16:33

Scancell Holdings Reports Tumour Rejection Data In Cancer Vaccine

LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that data from its second vaccine from its Moditope platform, Modi-2, showed T-cell response, tumour rejection and increased survival in

Read more
30 Oct 2018 14:36

Scancell pleased with progress on 'Moditope' vaccines

(Sharecast News) - Novel immunotherapies developer Scancell Holdings updated the market on the development of its second vaccine from its proprietary 'Moditope' platform, Modi-2, on Tuesday, reporting that pre-clinical data demonstrated that homocitrullinated peptides induced highly potent T-cell responses, tumour rejection and increased survival in murine models.

Read more
24 Oct 2018 12:28

Oxford Technology VCTs Mostly Report Drop In Net Asset Value

LONDON (Alliance News) - The Oxford Technology-managed venture capital trusts reported interim results on Wednesday, with all but one see a drop in net asset value.Oxford Technology Venture

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.